India will have more corona cases than US if it conducts more tests: Donald Trump

May 19: A Chinese laboratory has been developing a drug it believes has the power to bring the coronavirus pandemic to a halt.

The outbreak first emerged in China late last year before spreading across the world, prompting an international race to find treatments and vaccines.

A drug being tested by scientists at China's prestigious Peking University could not only shorten the recovery time for those infected, but even offer short-term immunity from the virus, researchers say.

Sunney Xie, director of the university's Beijing Advanced Innovation Center for Genomics, told AFP that the drug has been successful at the animal testing stage.

"When we injected neutralising antibodies into infected mice, after five days the viral load was reduced by a factor of 2,500," said Xie.

"That means this potential drug has (a) therapeutic effect."

The drug uses neutralising antibodies -- produced by the human immune system to prevent the virus infecting cells -- which Xie's team isolated from the blood of 60 recovered patients.

A study on the team's research, published Sunday in the scientific journal Cell, suggests that using the antibodies provides a potential "cure" for the disease and shortens recovery time.

Xie said his team had been working "day and night" searching for the antibody.

"Our expertise is single-cell genomics rather than immunology or virology. When we realised that the single-cell genomic approach can effectively find the neutralising antibody we were thrilled."

He added that the drug should be ready for use later this year and in time for any potential winter outbreak of the virus, which has infected 4.8 million people around the world and killed more than 315,000.

"Planning for the clinical trial is underway," said Xie, adding it will be carried out in Australia and other countries since cases have dwindled in China, offering fewer human guinea pigs for testing.

"The hope is these neutralised antibodies can become a specialised drug that would stop the pandemic," he said.

China already has five potential coronavirus vaccines at the human trial stage, a health official said last week.

But the World Health Organization has warned that developing a vaccine could take 12 to 18 months.

Scientists have also pointed to the potential benefits of plasma -- a blood fluid -- from recovered individuals who have developed antibodies to the virus enabling the body's defences to attack it.

More than 700 patients have received plasma therapy in China, a process which authorities said showed "very good therapeutic effects".

"However, it (plasma) is limited in supply," Xie said, noting that the 14 neutralising antibodies used in their drug could be put into mass production quickly.

Using antibodies in drug treatments is not a new approach, and it has been successful in treating several other viruses such as HIV, Ebola and Middle East Respiratory Syndrome (MERS).

Xie said his researchers had "an early start" since the outbreak started in China before spreading to other countries.

Ebola drug Remdesivir was considered a hopeful early treatment for COVID-19 -- clinical trials in the US showed it shortened the recovery time in some patients by a third -- but the difference in mortality rate was not significant.

The new drug could even offer short-term protection against the virus.

The study showed that if the neutralising antibody was injected before the mice were infected with the virus, the mice stayed free of infection and no virus was detected.

This may offer temporary protection for medical workers for a few weeks, which Xie said they are hoping to "extend to a few months".

More than 100 vaccines for COVID-19 are in the works globally, but as the process of vaccine development is more demanding, Xie is hoping that the new drug could be a faster and more efficient way to stop the global march of the coronavirus.

"We would be able to stop the pandemic with an effective drug, even without a vaccine," he said.

Washington, Jul 7: US Secretary of State Mike Pompeo on Monday (local time) confirmed that the White House is "looking at" banning the Chinese social media apps including TikTok.

"With respect to Chinese apps on people's cell phones, I can assure you the United States will get this one right too. I don't want to get out in front of the President [Donald Trump], but it's something we're looking at," Pompeo was quoted by CNN during an interview with Fox News.

He said people should only download the app, "if you want your private information in the hands of the Chinese Communist Party."

Responding to his comments, a TikTok spokesperson said, "TikTok is led by an American CEO, with hundreds of employees and key leaders across safety, security, product and public policy here in the US."

"We have no higher priority than promoting a safe and secure app experience for our users.  We have never provided user data to the Chinese government, nor would we do so if asked," the spokesperson added.

The US politicians have repeatedly criticised TikTok, owned by Beijing-based startup ByteDance, of being a threat to national security because of its ties to China.

Recently, India banned 59 Chinese apps including TikTok following a violent standoff with Chinese troops. This move was lauded by the US officials.

Washington, Feb 25: Democratic presidential front-runner Senator Bernie Sanders on Monday slammed President Donald Trump for selling weapons to India, saying that the US should instead partner with New Delhi to fight climate change to save the planet.

Sanders, who has won the Nevada and New Hampshire primaries and tied in Iowa, made the comments after Trump, who is on a two-day visit to India, on Monday announced that the US will sign defence trade deals worth USD 3 billion with India.

In an address at a massive "Namaste Trump" rally at Motera stadium in Ahmedabad, Trump announced that deals to sell state-of-the-art military helicopters and other equipment worth over USD 3 billion will be sealed with India on Tuesday.

“Instead of selling USD 3 billion in weapons to enrich Raytheon, Boeing and Lockheed, the United States should be partnering with India to fight climate change,” Sanders said in a tweet, the first by a Democratic presidential candidate on Trump's India visit.

“We can work together to cut air pollution, create good renewable energy jobs, and save our planet,” he said.

However, a former White House official defended the US' decision to sell arms and weapons to India.

“I'm proud of my service in the White House, in which we poured enormous energy into deepening climate and green tech cooperation w/ India... and also advancing security cooperation and defense sales. I'd like to think both can be part of a strong, values-based partnership,” Joshua White said.

According to the US State Department, India plays a vital role in the US vision for a free and open Indo-Pacific.

In 2016, the US designated India as a Major Defence Partner. Commensurate with this designation, India in 2018 was granted Strategic Trade Authorization tier 1 status, which allows New Delhi to receive license-free access to a wide range of military and dual-use technologies that are regulated by the Department of Commerce.

Bilateral defence trade with India in a little over a decade has increased from near zero in 2008 to USD20 billion.

Among some of the key foreign military sales notified to Congress include MH-60R Seahawk helicopters (USD2.6 billion), Apache helicopters (USD2.3 billion), P-8I maritime patrol aircraft (USD3 billion), and M777 howitzers (USD737 million).

India was the first non-treaty partner to be offered a Missile Technology Control Regime Category-1 Unmanned Aerial System – the Sea Guardian UAS manufactured by General Atomics.

The State Department is also advocating for the Lockheed Martin F-21 and Boeing F/A-18 – two state of the art fighter aircraft that India is currently evaluating.

These platforms provide critical opportunities to enhance India's military capabilities and protect shared security interests in the Indo-Pacific region, it argued.

The top categories of DCS to India include aircraft, electronics and gas turbine engines.